報價延遲最少15分鐘:2026/11/04 14:31 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.09 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-16.62/-1.05
|
|
企業價值
9.95M
|
| 資產負債 |
|
每股賬面淨值
3.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
54.23K
|
|
每股收益
1.71
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class ofdrugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discoveryand development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment. |
